Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Generic Zyrtec

This article was originally published in The Tan Sheet

Executive Summary

FDA grants final approval for McNeil Consumer Healthcare's generic Zyrtec to nine firms, the agency announces Dec. 27. Actavis, Apotex, Caraco Pharmaceutical Laboratories, Mylan Pharmaceuticals, Par Pharmaceutical Companies, Perrigo, Ranbaxy Laboratories, Sandoz and Wockhardt will offer the cetirizine HCl allergy and hives treatment in 5 mg and 10 mg tablets. FDA approved prescription-strength Zyrtec for over-the-counter sale Nov. 16, one week after approving McNeil's switch application for its Zyrtec-D allergy treatment decongestant combination product (1"The Tan Sheet" Nov. 12, 2007, p. 9). OTC Zyrtec is expected to be available for retail sale in late January...

You may also be interested in...



Zyrtec-D Switch Approved – J&J Will Launch Behind The Counter This Year

FDA approved Johnson & Johnson's bid to switch prescription antihistamine/nasal decongestant Zyrtec-D to nonprescription status, but the firm is still awaiting a reply on single-ingredient Zyrtec

US FDA And NIST Form Partnership To Boost Advanced Manufacturing Techniques

The US FDA and NIST have agreed to help industry modernize and update pharmaceutical manufacturing methods and to improve supply chain resilience.

Medtronic Looks To Adaptive DBS To Advance Treatment Of Parkinson’s Disease

Medtronic is sponsoring a trial to evaluate its adaptive deep brain stimulation technology, a unique feature of the Percept PC device for treating Parkinson’s disease.

Topics

UsernamePublicRestriction

Register

OM013164

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel